This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HOOK HOOKIPA Pharma (HOOK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsInsider TradesTrendsBuy This Stock About HOOKIPA Pharma Stock (NASDAQ:HOOK) Get HOOKIPA Pharma alerts:Sign Up Key Stats Today's Range$1.11▼$1.1550-Day Range$1.12▼$1.1952-Week Range$0.81▼$1.65Volume431 shsAverage Volume11,089 shsMarket Capitalization$14.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview HOOKIPA Pharma Inc. is a clinical-stage biotechnology company focused on the development of virus-based immunotherapies and vaccines. The company operates two complementary platform technologies—an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system—designed to stimulate both humoral and cellular immune responses. By combining these platforms, HOOKIPA aims to address infectious diseases and drive novel immuno-oncology treatments. In the infectious disease arena, HOOKIPA’s pipeline includes prophylactic vaccine candidates targeting pathogens such as cytomegalovirus (CMV) in transplant settings and other viral threats. The arenavirus-based platform is leveraged to induce strong T-cell responses against persistent viruses, while the MVA vector is optimized for broader antibody and T-cell activation. Preclinical and early clinical data have underscored the potential of these approaches to provide durable immunity with a favorable safety profile. Beyond infectious disease, HOOKIPA is advancing immuno-oncology programs that employ its vector systems to generate anti-tumor immune responses. These candidates are engineered to present tumor-associated antigens, aiming to recruit and expand cytotoxic T cells within the tumor microenvironment. This dual focus on both prophylactic and therapeutic indications reflects the company’s strategy to harness its platform versatility across multiple disease areas. Founded in 2016, HOOKIPA Pharma is headquartered in Vienna, Austria, with a U.S. subsidiary based in New York. The company’s leadership team comprises experienced executives and scientific founders who have previously held senior roles in biopharmaceutical research and development. HOOKIPA continues to collaborate with academic institutions and industry partners to advance its clinical pipeline and expand the reach of its novel immunotherapy platforms.AI Generated. May Contain Errors. Read More Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HOOKIPA Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HOOK Stock News HeadlinesHOOKIPA PharmaApril 6, 2026 | fool.comHOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail TherapeuticsMarch 27, 2026 | markets.businessinsider.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)HOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail TherapeuticsFebruary 3, 2026 | quiverquant.comQHOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail TherapeuticsFebruary 3, 2026 | globenewswire.comHOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead SciencesOctober 31, 2025 | quiverquant.comQHOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to GileadOctober 31, 2025 | globenewswire.comHOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead SciencesJuly 18, 2025 | quiverquant.comQSee More Headlines HOOK Stock Analysis - Frequently Asked Questions How were HOOKIPA Pharma's earnings last quarter? HOOKIPA Pharma Inc. (NASDAQ:HOOK) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.62. HOOKIPA Pharma had a negative trailing twelve-month return on equity of 120.09% and a negative net margin of 785.66%. When did HOOKIPA Pharma's stock split? Shares of HOOKIPA Pharma reverse split before market open on Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did HOOKIPA Pharma IPO? HOOKIPA Pharma (HOOK) raised $90 million in an IPO on Thursday, April 18th 2019. The company issued 6,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. What other stocks do shareholders of HOOKIPA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/15/2025Today7/11/2026Next Earnings (Estimated)8/07/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOOK CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees160Year Founded2011Profitability EPS (Trailing Twelve Months)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.50 million Net Margins-785.66% Pretax Margin-785.15% Return on Equity-120.09% Return on Assets-77.14% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual Sales$9.35 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.27Miscellaneous Outstanding Shares12,330,000Free Float11,787,000Market Cap$14.18 million OptionableOptionable Beta0.85 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:HOOK) was last updated on 7/12/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredExecutive order could send gold to 6,000 per ounceExecutive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...Cedar Gold Group | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
